Literature DB >> 9851772

Rapid diagnosis and identification of cross-over sites in patients with glucocorticoid remediable aldosteronism.

A A MacConnachie1, K F Kelly, A McNamara, S Loughlin, L J Gates, G C Inglis, A Jamieson, J M Connell, N E Haites.   

Abstract

Glucocorticoid remediable aldosteronism (GRA) is an autosomal dominant cause of primary aldosteronism and high blood pressure resulting from a chimeric 11beta-hydroxylase/aldosterone synthase gene. Abnormal expression of aldosterone synthase causes primary aldosteronism, which can be inhibited by glucocorticoids. Diagnosis of GRA has depended on the identification of a restriction enzyme product in genomic DNA of affected individuals. Recently, a two-tube long PCR method was described that allowed diagnosis of GRA in a kindred in Australia. A similar long PCR method confirmed the diagnosis of GRA in members of five northeastern Scotland families previously identified by Southern blotting and detected affected members of five GRA families previously identified in Glasgow. A multiplex PCR protocol is described here that allows the control aldosterone synthase amplification and chimeric gene amplification to be carried out in the same tube. We describe the regions of cross-over in each of 10 kindreds identified in Scotland. To identify cross-over regions in each of the kindreds, the chimeric long PCR product was cloned and sequenced. Five cross-over sites were identified ranging from intron 2 to exon 4, indicating the reliability of the method in identifying chimeric genes resulting from different sites of cross-over.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9851772     DOI: 10.1210/jcem.83.12.5309

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

Review 1.  Progress in molecular-genetic studies on congenital adrenal hyperplasia due to 11beta-hydroxylase deficiency.

Authors:  Li-Qiang Zhao; Su Han; Hao-Ming Tian
Journal:  World J Pediatr       Date:  2008-05       Impact factor: 2.764

2.  A de novo unequal cross-over mutation between CYP11B1 and CYP11B2 genes causes familial hyperaldosteronism type I.

Authors:  C A Carvajal; C B Stehr; P A González; E M Riquelme; T Montero; M J Santos; A M Kalergis; C E Fardella
Journal:  J Endocrinol Invest       Date:  2010-07-13       Impact factor: 4.256

Review 3.  Genetic information in the diagnosis and treatment of hypertension.

Authors:  Maciej Tomaszewski; Lukas Zimmerli; Fadi J Charchar; Anna F Dominiczak
Journal:  Curr Hypertens Rep       Date:  2006-08       Impact factor: 5.369

4.  GRAde: a long-read sequencing approach to efficiently identifying the CYP11B1/CYP11B2 chimeric form in patients with glucocorticoid-remediable aldosteronism.

Authors:  Yu-Ching Wu; Chia-I Chen; Peng-Ying Chen; Chun-Hung Kuo; Yi-Hsuan Hung; Kang-Yung Peng; Vin-Cent Wu; Jyy-Jih Tsai-Wu; Chia-Lang Hsu
Journal:  BMC Bioinformatics       Date:  2022-01-10       Impact factor: 3.169

5.  Characteristics and Outcomes in Primary Aldosteronism Patients Harboring Glucocorticoid-Remediable Aldosteronism.

Authors:  Chung-Yi Cheng; Hung-Wei Liao; Kang-Yung Peng; Tso-Hsiao Chen; Yen-Hung Lin; Jeff S Chueh; Vin-Cent Wu
Journal:  Biomedicines       Date:  2021-12-02

Review 6.  A systematic review of pathophysiology and management of familial hyperaldosteronism type 1 in pregnancy.

Authors:  Viola Sanga; Teresa Maria Seccia; Gian Paolo Rossi
Journal:  Endocrine       Date:  2021-05-27       Impact factor: 3.633

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.